Financial Performance - Q3 Fiscal 2025 - Revenue increased by 8.7% year-over-year to $80.7 billion[13] - Adjusted diluted EPS increased 19.8% year-over-year to $4.00[10, 12] - Consolidated adjusted operating income grew by 20.6% year-over-year[12] Segment Performance - Q3 Fiscal 2025 - U S Healthcare Solutions segment revenue increased by 8.5% to $72.9 billion, with operating income up 29.1% to $0.9 billion[15, 16] - International Healthcare Solutions segment revenue increased by 10.5% to $7.8 billion, but operating income decreased by 12.9% to $156.2 million[17, 18] - On a constant currency basis, International Healthcare Solutions revenue increased by 8.8% and operating income decreased by 16.2%[17, 18] Fiscal Year 2025 Guidance - Cencora updated its fiscal year 2025 adjusted diluted EPS guidance to a range of $15.85 to $16.00[10] - The company anticipates consolidated revenue growth of approximately 9%[20] - Adjusted operating income is projected to increase by 15% to 16%[20]

Second Quarter 2025 Performance - Second quarter revenue reached $148 million, with organic revenue growth of 6%[13] - Adjusted Earnings Per Share (EPS) increased 31% to $0.21, and Adjusted EBITDA margin increased 23%[13] - Surgical Solutions revenue increased 11% compared to the prior year quarter, driven by double-digit growth in Ultrasonics[39] - Restorative Therapies revenue declined 32% compared to the prior year quarter due to the divestiture of the Advanced Rehabilitation Business, while EXOGEN grew 11%[39] - Pain Treatments revenue increased 1% compared to the prior year quarter[39] Financial Metrics and Guidance - Adjusted Gross Margin increased 50 basis points due to improved product mix[40] - The company ended the second quarter with $33 million in cash and $341 million in debt outstanding[48] - Cash from operations was an inflow of $26 million in the second quarter[48] - The company reaffirms its 2025 financial guidance, projecting net sales in the range of $560 million to $570 million, representing organic growth of 6% to 8%[52] - Adjusted EBITDA is expected to be in the range of $112 million to $116 million, and Adjusted Earnings Per Share is projected to be in the range of $0.64 to $0.68[52] Strategic Initiatives and Future Outlook - The company received FDA 510(k) clearance for StimTrial and TalisMann, Peripheral Nerve Stimulation (PNS) products, targeting the chronic peripheral pain market[18, 20] - The PNS market is estimated to be growing above 20% annually in the U S and is expected to exceed $500 million by 2029, with an expected total addressable market of approximately $2 billion[20] - The company plans to invest in a direct sales force in the second half of 2025 and expects TalisMann and StimTrial to potentially generate $100 million or more of revenue[27] - The company forecasts at least 100 basis points of Adjusted EBITDA margin expansion in 2025[30] - The company expects cash from operations in 2025 to nearly double compared to 2024 and expects to reduce net leverage to below 2 5 times by the end of 2025[30, 48]

Financial Performance - Total revenue for Q2 2025 reached $489.93 million, reflecting a 12% year-over-year increase[66] - Creative Subscriptions Annualized Recurring Revenue (ARR) stood at approximately $1.4 billion as of June 30, 2025, a 10% increase year-over-year[11, 24] - Total bookings for Q2 2025 amounted to $509.92 million, representing an 11% year-over-year growth[66] - The company anticipates generating a free cash flow (FCF) margin of 30-31% in 2025[58] - Non-GAAP gross margin was 70% in Q2 2025[67] Business Segments - Partners revenue for Q2 2025 was $183.32 million, a 24% increase year-over-year[11, 73] - Transaction revenue for Q2 2025 reached $63.55 million, an 18% increase year-over-year[11, 73] User Cohorts and Marketing - New cohort bookings growth accelerated to 14% in Q2 2025 over the Q2 2024 cohort[36] - The company estimates approximately $18.4 billion in expected future bookings over the next 10 years from existing cohorts[45] Geographic Reach - Approximately 40% of the company's revenue comes from outside North America[11] Acquisition - Wix acquired Base44 in June 2025, which is projected to generate $40-$50 million of ARR by the end of 2025[17]

Valens Semiconductor (NYSE:VLN) August 2025 GAAP and non-GAAP Measures Certain statements in this presentation (this "Presentation") are "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that pred ...

Earnings Conference Call Presentation Q3 FY25 August 6, 2025 Pro Forma and Non-GAAP Measures This presentation includes the presentation and discussion of pro forma financial information that incorporates the results of Jacobs' Critical Mission Solutions and Cyber & Intelligence businesses ("CMS") prepared in accordance with the requirements of Article 11 of Regulation S-X. This presentation also includes the presentation and discussion of Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, Adjust ...

Second Quarter 2025 Financial Results Call 1 Disclaimer Certain statements in this presentation may be considered "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward- looking statements generally relate to future events or Holley's future financial or operating performance. For example, projections of future revenue and adjusted EBITDA and other metrics, along with statements regarding the impact of or ...

Financial Performance - Q2 2025 - Net sales reached $60 billion, a 102% increase compared to the same period last year[12] - Gross profit was $12 billion, up by 49%, but the gross profit margin decreased by 100 basis points to 208%[12] - Operating income decreased by 30% to $420 million, while non-GAAP operating income increased by 18% to $520 million[12] - Net income decreased by 35% to $271 million, but non-GAAP net income per diluted share increased by 39% to $260[12] Sales by Channel - Q2 2025 - Corporate sales increased by 176% to $25815 million[13] - Small Business sales increased by 126% to $4313 million[13] - Healthcare sales increased significantly by 241% to $7285 million[13] - Education sales experienced a decline of 109%, reaching $9067 million[13] Liquidity and Cash Flow - Total debt was $56327 million as of June 30, 2025[16] - Free cash flow for the quarter was $1334 million, and adjusted free cash flow was $2101 million[18] - The company returned $515 million year-to-date to shareholders through share repurchases and dividends[19] 2025 Outlook - The company anticipates U S IT growth plus a premium target of approximately 200 to 300 basis points[21] - The company expects low-to-mid single-digit growth in gross profit[21] - The company projects low-single-digit growth in non-GAAP net income per diluted share[21]

Defining the next era of commerce August 6, 2025 Advisories This presentation contains forward-looking statements and forward looking information (collectively, "forward-looking statements") that are based on our management's current estimates, beliefs and assumptions and management's perception of historic trends, current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. These statements may be identified by words such as "expect ...

Financial Performance - Consolidated net sales increased by approximately 1% year-over-year to ~$3.7 billion in Q3 FY25[11] - Adjusted EBITDA increased by $24 million year-over-year to $226 million in Q3 FY25, with a margin increase of 60 bps[11, 12] - Free cash flow was $115 million in Q3 FY25[11] - The company returned $50 million to shareholders through share repurchases in Q3, bringing the year-to-date total to $75 million, representing approximately 4% of shares outstanding[11, 12] - Adient is raising its FY25 revenue and EBITDA guidance[12] Regional Performance - Americas sales outperformed the market by 300 bps due to favorable volume/mix and full run-rate of key programs[32] - EMEA sales underperformed the broader market mainly due to customer mix and intentional portfolio actions[32] - Asia sales growth outpaced the broader market by 700 bps, driven by customer launches reaching full production volumes[32] Debt and Capital Structure - Cash balance was $860 million as of June 30, 2025[11] - Gross debt was approximately $2.4 billion and net debt was approximately $1.5 billion[11] - Net leverage ratio on a trailing twelve-month basis is 1.7x, within the targeted range of 1.5x-2.0x[44] Outlook - Consolidated revenue is expected to be approximately $14.4 billion[46] - Adjusted EBITDA is expected to be approximately $875 million[46] - Capital expenditures are expected to be approximately $150 million-$170 million[46]

Financial Performance - Q2 2025 revenues reached $49.8 million, driven by systems sales and AIC, but below the midpoint of guidance due to consumables and service headwinds[10, 21] - The adjusted EBITDA margin was -2.3%[10] - Non-GAAP gross margin decreased to 46.3% in Q2 2025, compared to 48.6% in Q2 2024, primarily due to a lower portion of consumables revenue in the sales mix[24, 25] - Non-GAAP operating expenses decreased to $26.7 million in Q2 2025 from $28 million in Q2 2024[27] - Cash, deposits, and marketable securities were approximately $489 million at the end of Q2 2025[31] Market Dynamics - Impressions grew 4.7% year-over-year to 222.7 million, with strong double-digit growth from top customers in DTG and R2R[11, 37] - Annual recurring revenue from AIC grew to $18.9 million[10, 39] Future Outlook - The company expects low single-digit growth in H2[15] - Q3 2025 revenues are expected to be in the range of $49 million to $55 million, with an adjusted EBITDA margin between -3% and 3%[33]